PharmaShots | Incisive News in 3 Shots

Subscribe Now

RESONATE-2

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

PharmaShots Interview: Janssen's Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

July 19, 2021

AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

AbbVie Reports Results of Imbruvica (ibrutinib) in Two P-III Studies as 1L Treatment for Chronic Lymphocytic Leukemia

December 8, 2020

Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

December 7, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us